Visibility of prostate cancer on transrectal ultrasound during fusion with multi-parametric magnetic resonance imaging for biopsy

Publication date: Available online 6 February 2016
Source:Clinical Imaging
Author(s): Wendy J.M. van de Ven, J.P. Michiel Sedelaar, Marloes M.G. van der Leest, Christina A. Hulsbergen-van de Kaa, Jelle O. Barentsz, Jurgen J. Fütterer, Henkjan J. Huisman
ObjectivesTo determine TRUS visibility of MR lesions.MethodsData from 34 patients with 56 MR lesions and prostatectomy was used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to PIRADS and Gleason scores.ResultsTRUS visibility occurred in 43% of all MR lesions and 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS visible lesions had a Gleason 4 or 5 component.ConclusionsAlmost half of the MR lesions were visible on TRUS. TRUS visible lesions were more aggressive than TRUS invisible lesions.



from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1KzMYDF
via IFTTT